The metabolic–dermatologic axis: Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide agonists as emerging immunometabolic therapies for obesity-associated skin disease

Clinics in Dermatology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles